F8 and hemophilia A: If rFVIIa and aPCC are not effective in bleeding control when used as single therapeutic agent, a concomitant use of both BPAs may be considered as reported in several case series of patients with congenital or acquired hemophilia A and anti-FVIII inhibitors.